Back to Search
Start Over
A Treatment-free Interval Allowed by Ponatinib as Fourth-line Therapy
- Source :
- Cancer Diagn Progn
- Publication Year :
- 2021
- Publisher :
- International Institute of Anticancer Research, 2021.
-
Abstract
- Background: The third-generation tyrosine kinase inhibitor ponatinib has demonstrated high clinical efficacy in the setting of patients with resistant chronic phase chronic myeloid leukemia (CML), also inducing deep molecular responses. However, ponatinib-related cardiovascular toxicities make management challenging, especially of those patients with CML with previous cardiovascular comorbidities. Case Report: We report on the efficacy of ponatinib treatment used as fourth-line therapy in a 55-year-old woman affected by significant comorbidities (mainly cardiovascular) present before the diagnosis of CML. Ponatinib therapy induced a rapid and excellent clinical response, with the achievement of a durable deep molecular response that allowed us to propose a strategy of treatment discontinuation in order to reduce drug-related toxicities. Conclusion: A strategy of a treatment-free interval might represent a useful clinical tool in those patients with CML who achieve a durable deep molecular response but are also affected by significant comorbidities in order to minimize the risk of ponatinib-related toxicities.
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Cancer Diagn Progn
- Accession number :
- edsair.doi.dedup.....d4e7bc946c84acf5458490449a63b11d